GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anti-Microbial Savior BioteQ Co Ltd (ROCO:6864) » Definitions » Debt-to-Equity

Anti-Microbialvior BioteQ Co (ROCO:6864) Debt-to-Equity : 0.01 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Anti-Microbialvior BioteQ Co Debt-to-Equity?

Anti-Microbialvior BioteQ Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$1.38 Mil. Anti-Microbialvior BioteQ Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$0.00 Mil. Anti-Microbialvior BioteQ Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$121.05 Mil. Anti-Microbialvior BioteQ Co's debt to equity for the quarter that ended in Dec. 2023 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Anti-Microbialvior BioteQ Co's Debt-to-Equity or its related term are showing as below:

ROCO:6864' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01   Med: 0.03   Max: 0.07
Current: 0.01

During the past 6 years, the highest Debt-to-Equity Ratio of Anti-Microbialvior BioteQ Co was 0.07. The lowest was 0.01. And the median was 0.03.

ROCO:6864's Debt-to-Equity is ranked better than
99.91% of 1060 companies
in the Biotechnology industry
Industry Median: 0.14 vs ROCO:6864: 0.01

Anti-Microbialvior BioteQ Co Debt-to-Equity Historical Data

The historical data trend for Anti-Microbialvior BioteQ Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anti-Microbialvior BioteQ Co Debt-to-Equity Chart

Anti-Microbialvior BioteQ Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial 0.07 0.03 0.07 0.02 0.01

Anti-Microbialvior BioteQ Co Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only 0.07 0.08 0.02 0.02 0.01

Competitive Comparison of Anti-Microbialvior BioteQ Co's Debt-to-Equity

For the Biotechnology subindustry, Anti-Microbialvior BioteQ Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anti-Microbialvior BioteQ Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anti-Microbialvior BioteQ Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Anti-Microbialvior BioteQ Co's Debt-to-Equity falls into.



Anti-Microbialvior BioteQ Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Anti-Microbialvior BioteQ Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Anti-Microbialvior BioteQ Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anti-Microbialvior BioteQ Co  (ROCO:6864) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Anti-Microbialvior BioteQ Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Anti-Microbialvior BioteQ Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Anti-Microbialvior BioteQ Co (ROCO:6864) Business Description

Traded in Other Exchanges
N/A
Address
Sec.1, Huandong Road, 1 Floor, No. 2, Ln. 31, Xinshi District, Tainan, TWN, 741
Anti-Microbial Savior BioteQ Co Ltd is engaged in drug research and development as well as development and technology patenting of medical fungi.

Anti-Microbialvior BioteQ Co (ROCO:6864) Headlines

No Headlines